Beta-Blockers with Least HDL Effects
Vasodilating beta-blockers with beta-2 agonist activity, specifically celiprolol, have the most favorable HDL profile and actually increase HDL cholesterol rather than decrease it. 1, 2
Understanding the HDL Problem with Beta-Blockers
The 2022 Hypertension guidelines clearly identify that nonselective beta-blockers lower HDL cholesterol and increase triglycerides 3. This adverse metabolic effect varies significantly based on the beta-blocker's selectivity and ancillary properties.
Ranking Beta-Blockers by HDL Impact (Worst to Best)
Most Harmful to HDL
- Propranolol (nonselective): Causes the most pronounced HDL reduction (-30 to -32%) and triglyceride elevation (+33 to 43%) 2
- Atenolol (beta-1 selective): Despite selectivity, produces similar qualitative effects as propranolol but less severe (HDL -15 to -19%, TG +23 to 30%) 2. The guidelines specifically note atenolol has "untoward metabolic effects like nonselective beta-blockers" 3
Intermediate Effects
- Bisoprolol (highly beta-1 selective): More favorable than atenolol—increases triglycerides (+20 to 28%) but does not significantly affect HDL-C 1, 2
- Beta-blockers with ISA (pindolol, mepindolol): Pindolol shows the most favorable profile among traditional beta-blockers, actually increasing HDL cholesterol (+8 to 14%) and improving the HDL/total cholesterol ratio 4. Mepindolol increases TG (+14 to 25%) but doesn't significantly affect HDL 2
Best Option for HDL Preservation
Celiprolol (highly cardioselective with beta-2 partial agonism): This is the clear winner, as it:
- Significantly increases HDL-C (not just neutral, but beneficial)
- Decreases total cholesterol, LDL-C, and triglycerides (-14 to -21%)
- Improves overall lipid profile 1, 2
Clinical Algorithm for Selection
When HDL preservation is a priority:
First choice: Celiprolol 400 mg/day—the only beta-blocker that improves rather than worsens lipid profile 1, 2
Second choice: Pindolol (with marked ISA)—increases HDL and improves HDL/total cholesterol ratio 4
Third choice: Bisoprolol—neutral effect on HDL (doesn't lower it) 1, 2
Avoid: Propranolol, atenolol, and other nonselective agents without ISA in patients with dyslipidemia concerns
Important Caveats
The guidelines note that beta-1 selectivity alone is insufficient to prevent metabolic effects—atenolol demonstrates this clearly 3. The key differentiating features are:
- Vasodilating properties (beta-2 agonism)
- Intrinsic sympathomimetic activity (ISA)
These ancillary properties, particularly in celiprolol, explain why it uniquely improves rather than worsens the lipid profile 1, 2.
Clinical pearl: In hypercholesterolemic hypertensive patients studied for 18 months, celiprolol was the only beta-blocker that significantly improved all lipid parameters, making it the evidence-based choice when HDL preservation matters 1.